News

Researchers solve full-length structure of a Janus kinase

John Carey
By John Carey
March 26, 2022

The breakthrough came on molecular biologist Christopher Garcia’s birthday.

For more than 20 years, his team and others around the world had been chasing an elusive quarry – the 3D structure of a crucial signaling protein in cells. In late 2021, his electron microscope images of the molecule started to come into focus. On December 8, postdoc Naotaka Tsutsumi and graduate student Caleb Glassman sent him an email with a startlingly clear picture of the protein latched on to a key receptor. “I was sitting in a meeting, and I realized we had it,” recalls Garcia, a Howard Hughes Medical Institute Investigator at Stanford University. “I immediately left the meeting and ran back to the lab.”

Eric Smith/Chris Garcia/HHMI
When a cytokine (green) binds to receptors (teal), two parts of the Janus kinase protein (pink) come together, activating it to send signals inside a cell. In some cancers, mutations in the kinase lock it together, keeping it abnormally active.

Glassman, who had just moved to Boston for a Harvard postdoc, canceled his planned backcountry trip, and rushed back to Stanford. “I wanted to finish what Naotaka and I had started,” he explains. Then the three researchers worked around the clock to nail the complete structure of the protein, known as a Janus kinase, and beat competing labs to the discovery. “It was a big horse race between many great groups worldwide, and we were sprinting towards the finish line,” Garcia says. On December 26, they rushed a manuscript to the journal Science, which published the work on March 10, 2022.

Garcia’s team has nabbed not just the full structure of a vitally important signaling molecule, but also the mechanism for how these kinases work, which had been “a fundamental question in biology,” says John O’Shea, an immunologist at the National Institutes of Health who helped to develop one of the first drugs to block Janus kinase function and was not involved with the new research. Because the proteins can go awry in disease, the results could lead to new and better drugs against certain cancers. “It’s amazing work,” O’Shea says. 

Chipping away

Janus kinases are one of the communication whizzes of the animal kingdom. They take signals that come from outside cells and pass the info along to molecules inside. Scientists have known for years that malfunctioning Janus kinases can cause disease. Some mutations that impair Janus kinases can severely curtail the body’s ability to fight off infection, causing a condition virtually identical to “bubble boy disease.” And when genetic glitches and exaggerated signals rev up the kinases too much, the result can be blood cancers like leukemia, and allergic or autoimmune diseases.

Researchers knew the shape of parts of the proteins, including related enzyme and regulatory regions at the end of the molecule, which earned them the name Janus kinases, after the two-faced mythological Roman god. And sophisticated drug screens have unearthed molecules that inhibit these proteins, giving doctors a way to treat some cancers and disorders like rheumatoid arthritis. But scientists developed the drugs without knowing the molecules’ full structure or how they become activated. So most of the current arsenal of nearly a dozen drugs, plus more in clinical trials, are relatively blunt instruments, blocking both healthy and mutated Janus kinases. They can still treat many diseases, from eczema to COVID-19, but also can cause a range of side effects.

Garcia wanted a more detailed view of the proteins but, as he learned when he first tried to image the molecules as a postdoc in 1995, it was a daunting challenge. The kinases are notoriously difficult to make in the lab. And they don’t easily form crystals, which scientists need to capture 3D structures using x-ray crystallography. So, for many years, Garcia and others could only view bits of the kinases at a time. “We kept chipping away without much to show for it,” he says.

In the last few years, the pieces began to fall into place. One key advance was a method called cryo-EM, where scientists freeze samples and then view them using an electron microscope. Another was the choice by Garcia’s team to study a mouse Janus kinase rather than a less stable human one. They also introduced a common cancer-causing mutation into the mouse kinase, which stabilized the molecule even further. 

Lighting a fire

Garcia’s team’s work reveals the structure of a Janus kinase called JAK1 and outlines the steps it uses to sends signals within cells.

First, receptor proteins stud cell membranes, poking from the inner and outer surfaces of the cell like a toothpick through a sandwich. Then, a single Janus kinase inside the cell attaches to the receptors, waiting for a signal. Next, molecules called cytokines approach the cell’s exterior, each binding to two receptors. The cytokines act like a bridge that pulls the two receptors even closer, Garcia explains. That brings the active ends of the Janus kinase together, switching them on. Like a match lighting a fire, the kinase relays a signal that tells genes to turn on or off.

The structure also reveals how the cancer-causing mutation short-circuits this messaging chain – by gluing two parts of the Janus kinase together. That causes the two active regions to stay switched on even when there are no outside cytokines, sparking uncontrolled activity that can trigger cancers.

Garcia hopes the new results could help scientists design better drugs that target only defective Janus kinases, allowing healthy versions to keep performing their normal duties. The work, he says, is an example of an “ideal situation in science, where solving a basic problem also has direct relevance for disease.”

This article originally appeared in HHMI News and was republished with permission. The Howard Hughes Medical Institute is the nation’s largest private supporter of academic biomedical research. You can read more stories about our scientists and programs at HHMI News.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
John Carey
John Carey

John Carey is a freelance writer in the Washington, D.C., area.

Related articles

From the journals: March 2019
John Arnst, Courtney Chandler, Isha Dey & Catherine Goodman
An essential debate
Rajendrani Mukhopadhyay

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

A membrane ATPase without transporter activity
Journal News

A membrane ATPase without transporter activity

Sept. 28, 2022

A classic article in the Journal of Biological Chemistry reflects on Guido Guidotti’s laboratory and the search for CD39.

The era of “smart” organelles
Annual Meeting

The era of “smart” organelles

Sept. 28, 2022

This symposium, Organelles, Mechanisms and Phase Properties of Cellular Quality Control, will be part of #DiscoverBMB 2023.

Lipids, lipids everywhere!
Annual Meeting

Lipids, lipids everywhere!

Sept. 27, 2022

This symposium, Lipid Dynamics and Signals in Membrane and Protein Structure, will be part of #DiscoverBMB 2023.

A target to prevent kidney injury by chemotherapy
Journal News

A target to prevent kidney injury by chemotherapy

Sept. 27, 2022

“Many people don’t realize that the side effects of chemotherapy are not limited to hair loss, diarrhea and nausea.”

Carbohydrates for life,  health and diseases
Annual Meeting

Carbohydrates for life, health and diseases

Sept. 27, 2022

This symposium, Frontiers in Carbohydrate Synthesis and Recognition, will be part of #DiscoverBMB 2023.

Learn, reflect and lead
Annual Meeting

Learn, reflect and lead

Sept. 26, 2022

This symposium, Educational Professional Development, will be part of #DiscoverBMB 2023 in March.